route of administration of biotech product parenteral route mentioning soluble carrier system &...
TRANSCRIPT
PRESENTATION ON
‘‘Route of administration of biotech product:
Parenteral route mentioning Soluble carrier system &
Particulate carrier system’’
Biotechnology
Biotech Product
Route of administration of biotech
products
Parenteral route of
administration for biotech
products
Carrier system drug
delivery
Particulate carrier
system
Soluble carrier system
Conclusion
OBJECTIVES
Use of living
systems, organisms, or parts of organisms
to manipulate in the genetic level
to develop products,
systems or environme
nts to benefit
BIO
TECH
NO
LOG
Y
produce new
substances or
perform new
functions
to modify the
genetic material of living
cells
made by using
biotechnical
methods
BIOTECH PRODUCTS
Methods to produce biotech products
• Recombinant DNA technology
• Fermentation• Tissue or cell culture
technology• Genetic engineering
EXAMPLES
•Avastin
Antibody
•Orencia
Fusion protein
•Leukine
Progenitor cells
stimulator
ROUTES OF ADMINISTRATION OF BIOTECH
PRODUCTS
Parenteral route
Oral route
Nasal route
Trans-mucosal
route
Parenteral Routeof Administration
• Intravenous
IV
• Intramuscular
IM
• Subcutaneous
SC
Intravenous Administration
Fastest way
Directly in one of superficial vein
Highest concentration can be achieved
ExampleAlteplaseReteplas
eTenectepl
ase
common with biotechnology-derived drugs,
particularly those used to treat chronic
conditions
Administered as a bolus into the
subcutis
the layer of skin directly below the
dermis and epidermis, collectively
referred to as the cutis
Subcutaneous Administration
Example Rheumatoid
Arthritis Products
Etanercept
Anakinra
Adalimumab
Insulin and hormones
administered as
subcutaneous injection
INTRAMASCULAR ADMINISTRATION
• Intramuscular administration of biotechnology-derived drugs is also commonly seen
• A technique used to deliver a medication deep into the muscles
• e.g. interferon β products have been shown to be less immunogenic when administered via intramuscular injection.
Adv
anta
ges Rapid administration of
solution
Avoids first pass metabolism
100% bioavailablePrevent the growth of
cancerous cells
IV nutrient therapy
Disadvantage
Painful & Fearful
Infection Supervisor required to administer
Disadvantage
Irreversible Coagulation
CARRIER SYSTEM
Biochemically inert (non-
toxic)
Non-immunogen
ic
Physically and chemically
stable in vivo and in vitro conditions
Carrier systems convey drugs to specific receptors and ligands and physically modulate components.
Overview of carrier system drug delivery
Particulate
Carrier system
Soluble carrier system
Others
CARRIER SYSTEM
PARTICULATE CARRIER SYSTEM
PAR
TIC
UL
ATE
C
AR
RIE
R S
YST
EM
Microspheres
Microcapsules
Nanoparticles
Aquasomes
Liposomes
Emulsions
Cellular carriers
Microspheres
Conjugating receptor specific moieties
Protein Targeting
Microspheres
Advantage• Cheap preparation
• implantation not necessary
Passage through barriers
Microspheres
Disadvantage
release
maybe
difficult
Prossible
interaction with
blood compon
ents
Microcapsules
Control release of peptides moieties
polymeric in nature
interfacial polymeriza
tion
or coacervate
phase separation
Permeability barrier
Microcapsules
Conventionally used
polymers
NylonGelatinPVAPolyurethane
Nanoparticles
Similar to microspheres targeted delivery specificity and
enhancement effective adjuvant
Met
hods Conventional
solution
Desolvation
in situ micellar polymerization
Nanoparticles
Example
CyanoacrylatePolymethacrylatePolystyreneAlbuminAcrylic resins
Aquasomes
self-assembling nanoconstructs
Immobilization of
bioactive molecules
Example: Aquasome-delivered insulin
Lipsomes
Spherical vesicles
concentric bilayers surrounding aqueous phases
Met
hods
DRV
Reverse phase evaporation
Lipsomes
Flexibility
nontoxic deposition
peptide and protein encapsulation
adjuvants
Emulsions
Colloid sized
droplets
protection from body
fluids
clinical acceptability
large scale production
Cellular carriers
Met
hods
Erythrocytes encapsulation
hemolysis
dialysis
electric field breakup
Soluble carrier system
The peptide /protein drugs can be conjugate with a polymer/macromolecule
Post-
Trans
lation
al
mod
ificat
ion
PEGylation
Glycosylation
Mannosylation
Others
PEGylation:
The attachment of PEG with therapeutic protein
Glycosylation The attachment of sugar moieties to protein to
form glycoprotein
Mannosylation: Conjugation of protein with Mannose
On-demand system
Self-regulated
system
Temper sensitive system
Pumps
Mechanical pump
osmotic pump
Control release micro-pump
Others
For improving therapeutic efficacy
Overcoming drawbacks associated with conventional dosage form.
Replacing existing traditional pharmaceuticals.
Conclusion
Almeida H, Amaral MH, Lobão P. Drugs Obtained by Biotechnology Processing. Brazilian Journal of Pharmaceutical Sciences, 2011; 47(2): 199-207.
Manda R, Dr. Suthakaran R, Kaya V, Fouziya BS. A Comparative Review of Recently Developed Particulate Drug Carrier Systems. World Journal of Pharmacy and Pharmaceutical Sciences, 2014; 3(11): 121-134.
Nagel Km, Karash AR. Biotechnology. In Lee M, Desai A, Editors. Gibaldi’s Drug Delivery Systems in Pharmaceutical Care. American Society of Health-System Pharmacists, Inc., 2007; pp 135-154.
Patel A, Cholkar K, Mitra AK. Recent developments in protein and peptide parenteral delivery approaches. Ther. Deliv., 2014; 5(3): 337–365.
Srikanth K, Gupta VRM, Manvi SR, Devanna N. Particulate Carrier Systems: A Review. International Research Journal of Pharmacy, 2012; 3(11): 22-26.
REFERENCES